P1162 Upadacitinib in Crohn’s Disease Patients: for what type of patients in real world setting ?

P Juillerat; M Martinho-Grueber; R Ruetsch; H Moubayed; M Vullièmoz-; P Michetti.

Journal ArticleOPEN ACCESS

P1162 Upadacitinib in Crohn’s Disease Patients: for what type of patients in real world setting ?

Juillerat P
Martinho-Grueber M
Ruetsch R
et al.

Journal of Crohn's and Colitis (2024) 18(Supplement_1) i2059-i2059

DOI: 10.1093/ecco-jcc/jjad212.1292

N/ACitations

5Readers

Abstract

Background: The oral selective JAK kinase inhibitor, Upadacitinib (UPA; Rinvoq®) has been shown to induce and maintain clinical response and remission in Crohn's disease (CD), but also in rheumatic and skin diseases. We report here on the largest Swiss experience in "off label" use of this drug.

Cite

CITATION STYLE

APA

Juillerat, P., Martinho-Grueber, M., Ruetsch, R., Moubayed, H., Vullièmoz-, M., & Michetti., P. (2024). P1162 Upadacitinib in Crohn’s Disease Patients: for what type of patients in real world setting ? Journal of Crohn’s and Colitis, 18(Supplement_1), i2059–i2059. https://doi.org/10.1093/ecco-jcc/jjad212.1292

P1162 Upadacitinib in Crohn’s Disease Patients: for what type of patients in real world setting ?

Abstract

Cite

Register to see more suggestions